

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Multiple sclerosis (MS)	DEAD box polypeptide 58 (DDX58; RIG-I); interferon induced with helicase C domain 1 (IFIH1; MDA5)	<p>Mouse studies suggest activating RIG-I or MDA5 could help treat MS. In a mouse model of MS, RNA ligands that activate RIG-I or MDA5 decreased inflammation, myelin damage and disease severity compared with vehicle. Next steps include determining biomarkers and endpoints for a clinical trial of one of the ligands.</p> <p>SciBX 5(1); doi:10.1038/scibx.2012.5 Published online Jan. 5, 2012</p>	Patent applications filed; available for licensing	<p>Dann, A. <i>et al. Nat. Neurosci.</i>; published online Dec. 4, 2011; doi:10.1038/nn.2964</p> <p>Contact: Marco Prinz, University of Freiburg, Freiburg, Germany e-mail: marco.prinz@uniklinik-freiburg.de</p>